Search

Craig S Mickanin

from Hopkinton, MA
Age ~54
Get Report
Also known as:
Craig Stephen Mickanin, Craig S Mickina, Craig N, Craig A
Phone and address:
7 Duffield Rd, Hopkinton, MA 01748
(508) 435-0225
Related to:
Philip Lyons
Connected to:
Belinda R Mickas, 51Patricia Mickavicz, 82Todd C Mickavicz, 47Janine A Micke, 56Tina M Micke, 62Tamika Mickeals, 34Paul W Mickee, 62Caroline D Mickel, 93Jacob H Mickel, 28Jimmy Mickel, 80

Craig Mickanin Phones & Addresses

  • 7 Duffield Rd, Hopkinton, MA 01748 (508) 435-0225
  • Basking Ridge, NJ
  • Cambridge, MA
  • Richmond, CA
  • Williamsburg, VA
  • Philadelphia, PA
  • Moorestown, NJ
  • Bernardsville, NJ
  • 7 Duffield Rd, Hopkinton, MA 01748

Publications

Us Patents

Mammary Gland Chemokine

View page
US Patent:
20020009735, Jan 24, 2002
Filed:
Mar 21, 2001
Appl. No.:
09/813492
Inventors:
Mark Labow - Westfield NJ, US
Craig Mickanin - Basking Ridge NJ, US
Umesh Bhatia - Los Gatos CA, US
International Classification:
C12Q001/68
G01N033/574
A61K038/19
US Classification:
435/006000, 435/007230, 424/085100
Abstract:
The present invention provides various methods for utilizing a polypeptide encoding a chemokine (MEC) and a polypeptide translated therefrom. The MEC chemokine is underexpressed in tumors, making the chemokine a useful marker for diagnosis and prognosis of adverse bodily reactions.

Tumor Necrosis Factor Receptor Related Protein-1 Gene And Protein

View page
US Patent:
20030059889, Mar 27, 2003
Filed:
Aug 28, 2002
Appl. No.:
10/231426
Inventors:
Dale Bodian - Whippany NJ, US
Mark Labow - Westfield NJ, US
Craig Mickanin - Basking Ridge NJ, US
International Classification:
C12Q001/68
C07H021/04
C07K014/715
C12P021/02
C12N005/06
US Classification:
435/069100, 435/320100, 435/325000, 530/350000, 536/023500, 435/006000
Abstract:
Disclosed is a tumor necrosis factor receptor related protein 1 gene and gene product. In particular, the invention relates to a protein that is homologous to known tumor necrosis factor receptors, nucleic acid molecules that encode such a protein, antibodies that recognize the protein, methods for diagnosing and treating disorders, such as inflammatory disorders, immune disorders, neurodegenerative disorders, cell proliferative disorders, cell differentiation disorders, apoptotic disorders, gastrointestinal and reproductive tract disorders, bone disorders, blood disorders and viral disorders, methods of identifying molecules that bind and/or modulate the activity of TRP-1 protein, and methods of identifying molecules that bind to a nucleic acid encoding TRP-1 protein and/or modulate the transcription or translation of the nucleic acid encoding TRP-1 protein.

Compositions And Methods For The Treatment Of Hemoglobinopathies

View page
US Patent:
20190010495, Jan 10, 2019
Filed:
Dec 26, 2016
Appl. No.:
16/066617
Inventors:
- Basel, CH
- Cambridge MA, US
Lloyd B. KLICKSTEIN - Newton MA, US
Reynald LESCARBEAU - Cambridge MA, US
Craig Stephen MICKANIN - Hopkinton MA, US
Kabungo MULUMBA - Cambridge MA, US
Seshidhar Reddy POLICE - Burlington MA, US
Jennifer SNEAD - San Diego CA, US
Susan C. STEVENSON - Ashland MA, US
Morag STEWART - Cambridge MA, US
Yi YANG - Belmont MA, US
Assignee:
NOVARTIS AG - Basel
INTELLIA THERAPEUTICS, INC. - Cambridge MA
International Classification:
C12N 15/113
A61P 7/00
A61K 35/15
Abstract:
The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.

Biomarkers Associated With Brm Inhibition

View page
US Patent:
20180258491, Sep 13, 2018
Filed:
Dec 22, 2017
Appl. No.:
15/853699
Inventors:
Zainab JAGANI - Cambridge MA, US
Gregory HOFFMAN - Cambridge MA, US
Frank Peter STEGMEIER - Acton MA, US
Craig Stephen MICKANIN - Cambridge MA, US
Assignee:
Novartis AG - Basel
International Classification:
C12Q 1/6886
C12N 15/113
G01N 33/574
Abstract:
The invention provides methods of detecting cancer biomarkers, such as one or more SWI/SNF complex mutations, in order to determine a cancer subject's amenability to therapeutic treatment with a BRM inhibitor. Kits, methods of screening for candidate FIRM inhibitors, and associated methods of treatment are also provided.

Biomarkers Associated With Brm Inhibition

View page
US Patent:
20160032402, Feb 4, 2016
Filed:
Mar 12, 2014
Appl. No.:
14/777211
Inventors:
Zainab JAGANI - Cambridge MA, US
Gregory HOFFMAN - Cambridge MA, US
Frank Peter STEGMEIER - Cambridge MA, US
Craig Stephen MICKANIN - Cambridge MA, US
Assignee:
Novartis AG - Basel
International Classification:
C12Q 1/68
G01N 33/574
C12N 15/113
Abstract:
The invention provides methods of detecting cancer biomarkers, such as one or more SWI/SNF complex mutations, in order to determine a cancer subject's amenability to therapeutic treatment with a BRM inhibitor. Kits, methods of screening for candidate BRM inhibitors, and associated methods of treatment are also provided.
Control profile
Craig S Mickanin from Hopkinton, MA, age ~54 Get Report